HEAL Stock Price | iShares Healthcare Innovation UCITS ETF USD (Acc) P/E, Revenue, EPS, & Forecasts

iShares Healthcare Innovation UCITS ETF USD (Acc) • HEAL

HEAL current price

$7.63+4.09%

Capital at risk.

About
Metrics
Sector breakdown
Regional breakdown
Top 10 Holdings
FAQs
News

-1.80%

+0.53%

-5.22%

+1.60%

+4.09%

MAX

+55.08%

About iShares Healthcare Innovation UCITS ETF USD (Acc)

Base currency

$ USD

Trading Cyrrency

USD

ISIN

IE00BYZK4776

Trading on

LSE

Ticker

HEAL

Fund manager

iShares

Key facts & metrics

BasicAdvanced

Fund size

$1.02B

income

Distributing

Expense Ratio

40.00%

Dividend Yield

0.91828

Valuation

Price to prospective earnings

20.03

Price to book

3.89

Price to sales

3.59

Price to cashflow

16.04

Price

52-week High

$8.20

52-week Low

$7.01

50-day moving average

$7.86

200-day moving average

$7.70

Technicals

YTD

2.15%

Year 1

5.54%

Year 3

5.53%

Year 5

3.48%

Year 10

0.00%

Volatility Year 1

15.41%

Volatility Year 3

15.86%

Expected Return Year 3

2.69%

Sharpe Ratio

0.40%

Growth

Long term projected earnings

10.43%

Historical earnings

3.66%

Sales

0.24%

Cash flow

14.72%

Book value

5.30%

Sector breakdown

Healthcare

% 98,62

Technology

% 1,38

Regional breakdown

North America

% 70,79

Europe

% 15,19

Asia

% 11,32

% 1,41

Australia

% 1,29

Top 10 Holdings

Argen-X

2.39%

Natera Inc

2.17%

Gilead Sciences

2.08%

UCB SA

2.03%

Insulet

2.02%

Bristol-Myers Squibb

2.01%

Intuitive Surgical Inc

1.89%

Illumina

1.87%

Boston Scientific

1.71%

Abbott Laboratories

1.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

What is the name of HEAL?

The name of HEAL is iShares Healthcare Innovation UCITS ETF USD (Acc).

What is the ticker of iShares Healthcare Innovation UCITS ETF USD (Acc)?

The primary ticker of iShares Healthcare Innovation UCITS ETF USD (Acc) is HEAL.

What is the ISIN of iShares Healthcare Innovation UCITS ETF USD (Acc)?

The ISIN of iShares Healthcare Innovation UCITS ETF USD (Acc) is IE00BYZK4776.

What are the costs of iShares Healthcare Innovation UCITS ETF USD (Acc)

The total expense ratio (TER) of iShares Healthcare Innovation UCITS ETF USD (Acc) amounts to 40.00% p.a. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately.

Does iShares Healthcare Innovation UCITS ETF USD (Acc) pay dividends?

Yes, iShares Healthcare Innovation UCITS ETF USD (Acc) does pay dividends.

What currency is iShares Healthcare Innovation UCITS ETF USD (Acc) traded in?

iShares Healthcare Innovation UCITS ETF USD (Acc) is traded in USD.

Is iShares Healthcare Innovation UCITS ETF USD (Acc) an accumulating or distributing ETF?

iShares Healthcare Innovation UCITS ETF USD (Acc) is distributing.

Who is the fund manager of “iShares Healthcare Innovation UCITS ETF USD (Acc)?

The fund manager of iShares Healthcare Innovation UCITS ETF USD (Acc) is iShares.

What is the fund size of iShares Healthcare Innovation UCITS ETF USD (Acc)?

The fund size of iShares Healthcare Innovation UCITS ETF USD (Acc) is $1.02B.

iShares Healthcare Innovation UCITS ETF USD (Acc) news

thumbs_up_down

•Neutral

PCE Data Lower Than Expected, NVO Falls on New Obesity Drug, AFRM Upgraded

Jenny Horne joins the Futures show with live reaction to the latest PCE inflation data. November rate rose just 0.1% from October, but on an annual basis checked in at 2.4% On the stock front, Novo Nordisk (NVO) slid sharply after disappointing clinical data for its new obesity drug CagriSema.

Schwab Network•13h ago

thumb_up_alt

•Positive

Novo Nordisk Stock: A Rare Buying Opportunity

As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a rare buying opportunity to buy NVO stock at about fair stock price, judging by the long-term average valuation ratios. The business experienced 22.7% YoY revenue growth in US dollars during Q3 FY2024 and managed to expand its EBIT margin to over 47% (+95 bps QoQ and +161 bps YoY).

Seeking Alpha•13h ago

thumb_down_alt

•Negative

Novo Nordisk shares drop after weight loss drug trial disappoints

Novo Nordisk (NYSE:NVO) shares plunged more than 20% before Friday's opening bell after the drugmaker reported results from a late-stage trial of its weight loss drug CagriSema that fell short of expectations. The company reported that patients in the trial achieved weight loss of 22.7% after 68 weeks, below the 25% it had previously guided.

Proactive Investors•13h ago